FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients

Neuroscience Letters

Volumn 479, Issue 1, 2010, Pages 22-25

  de Mena, Lorena ^a   Cardo, Lucía F ^a   Coto, Eliecer ^a,c   Miar, Ana ^a   Díaz, Marta ^a   Corao, Ana I ^a   Alonso, Belén ^a   Ribacoba, René ^b   Salvador, Carlos ^b   Menéndez, Manuel ^b   Morís, Germán ^b   Alvarez, Victoria ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b San Agustín Avilés and Alvarez Buylla Mieres ^*  (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

Author keywords

DNA polymorphisms; Genetic risk; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 20; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MICRORNA; MICRORNA 433; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; FGF20 PROTEIN, HUMAN; MIRN433 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL DEGENERATION; ONSET AGE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; CAUCASIAN; DNA SEQUENCE; GENETICS; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

3' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FIBROBLAST GROWTH FACTORS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; SPAIN; YOUNG ADULT;

EID: 77953701815     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.05.019     Document Type: Article

References (36)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Buyse I.M, Fang P., Hoon K.T., Amir R.E., Zoghbi H.Y., Roa B.B. Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: identification of several novel mutations and polymorphisms. Am. J. Hum. Genet. 2000, 67:1428-1436.
3. Clarimon J., Xiromerisiou G., Eerola J., Gourbali V., Hellstrom O., Dardiotis E., Peuralinna T., Papadimitriou A., Hadjigeorgiou G.M., Tienari P.J., Singleton A.B. Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients. BMC Neurol. 2005, 5:11.
4. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the Elderly Research Group. Neurology 2000, 54:S21-S23.
5. Duan R., Pak C., Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum. Mol. Genet. 2007, 16:1124-1131.
6. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N.Y. Acad. Sci. 2003, 991:1-14.
7. Fung H.C., Scholz S., Matarin M., Simon-Sanchez J., Hernandez D., Britton A., Gibbs J.R., Langefeld C., Stiegert M.L., Schymick J., Okun M.S., Mandel R.J., Fernandez H.H., Foote K.D., Rodriguez R.L., Peckham E., De Vrieze F.W., Gwinn-Hardy K., Hardy J.A., Singleton A. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006, 5:911-916.
8. Gao X., Scott W.K., Wang G., Mayhew G., Li Y.J., Vance J.M., Martin E.R. Gene-gene interaction between FGF20 and MAOB in Parkinson disease. Ann. Hum. Genet. 2008, 72:157-162.
9. Georges M., Coppieters W., Charlier C. Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease. Curr. Opin. Genet. Dev. 2007, 17:166-176.
10. Hauser M.A., Li Y.J., Takeuchi S., Walters R., Noureddine M., Maready M., Darden T., Hulette C., Martin E., Hauser E., Xu H., Schmechel D., Stenger J.E., Dietrich F., Vance J. Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum. Mol. Genet. 2003, 12:671-677.
11. Hebert S.S., De Strooper B. Molecular biology. miRNAs in neurodegeneration. Science (New York, NY) 2007, 317:1179-1180.
12. Hong C.J., Liu H.C., Liu T.Y., Lin C.H., Cheng C.Y., Tsai S.J. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset. Neurosci. Lett. 2003, 353:75-77.
13. Huang Y., Cheung L., Rowe D., Halliday G. Genetic contributions to Parkinson's disease. Brain Res. Brain Res. Rev. 2004, 46:44-70.
14. Ibanez P., Bonnet A.M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A., Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
15. Jeffers M., Shimkets R., Prayaga S., Boldog F., Yang M., Burgess C., Fernandes E., Rittman B., Shimkets J., LaRochelle W.J., Lichenstein H.S. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res. 2001, 61:3131-3138.
16. Karamohamed S., Latourelle J.C., Racette B.A., Perlmutter J.S., Wooten G.F., Lew M., Klein C., Shill H., Golbe L.I., Mark M.H., Guttman M., Nicholson G., Wilk J.B., Saint-Hilaire M., DeStefano A.L., Prakash R., Tobin S., Williamson J., Suchowersky O., Labell N., Growdon B.N., Singer C., Watts R., Goldwurm S., Pezzoli G., Baker K.B., Giroux M.L., Pramstaller P.P., Burn D.J., Chinnery P., Sherman S., Vieregge P., Litvan I., Gusella J.F., Myers R.H., Parsian A. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD study. Neurology 2005, 65:1823-1825.
17. Kosik K.S. The neuronal microRNA system. Nat. Rev. 2006, 7:911-920.
18. Mata I.F., Ross O.A., Kachergus J., Huerta C., Ribacoba R., Moris G., Blazquez M., Guisasola L.M., Salvador C., Martinez C., Farrer M., Alvarez V. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur. J. Neurol. 2006, 13:391-394.
19. Mencia A., Modamio-Hoybjor S., Redshaw N., Morin M., Mayo-Merino F., Olavarrieta L., Aguirre L.A., del Castillo I., Steel K.P., Dalmay T., Moreno F., Moreno-Pelayo M.A. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat. Genet. 2009, 41:609-613.
20. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 1999, 270:45-48.
21. Ohmachi S., Watanabe Y., Mikami T., Kusu N., Ibi T., Akaike A., Itoh N. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem. Biophys. Res. Commun. 2000, 277:355-360.
22. Rideout H.J, Dietrich P., Savalle M., Dauer W.T., Stefanis L. Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. J. Neurochem. 2003, 84:803-813.
23. Satake W., Mizuta I., Suzuki S., Nakabayashi Y., Ito C., Watanabe M., Takeda A., Hasegawa K., Sakoda S., Yamamoto M., Hattori N., Murata M., Toda T. Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population. Neuroreport 2007, 18:937-940.
24. Schneider B.L., Seehus C.R., Capowski E.E., Aebischer P., Zhang S.C., Svendsen C.N. Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum. Mol. Genet. 2007, 16:651-666.
25. Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Lyons K., Pahwa R., Stern M.B., Colcher A., Hiner B.C., Jankovic J., Ondo W.G., Allen F.H., Goetz C.G., Small G.W., Masterman D., Mastaglia F., Laing N.G., Stajich J.M., Slotterbeck B., Booze M.W., Ribble R.C., Rampersaud E., West S.G., Gibson R.A., Middleton L.T., Roses A.D., Haines J.L., Scott B.L., Vance J.M., Pericak-Vance M.A. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001, 286:2239-2244.
26. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
27. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
28. Steece-Collier K., Maries E., Kordower J.H. Etiology of Parkinson's disease: genetics and environment revisited. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13972-13974.
29. Valencia-Sanchez M.A., Liu J., Hannon G.J., Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006, 20:515-524.
30. van der Walt J.M., Noureddine M.A., Kittappa R., Hauser M.A., Scott W.K., McKay R., Zhang F., Stajich J.M., Fujiwara K., Scott B.L., Pericak-Vance M.A., Vance J.M., Martin E.R. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am. J. Hum. Genet. 2004, 74:1121-1127.
31. Wang G., van der Walt J.M., Mayhew G., Li Y.J., Zuchner S., Scott W.K., Martin E.R., Vance J.M. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet. 2008, 82:283-289.
32. Wider C., Dachsel J.C., Soto A.I., Heckman M.G., Diehl N.N., Yue M., Lincoln S., Aasly J.O., Haugarvoll K., Trojanowski J.Q., Papapetropoulos S., Mash D., Rajput A., Rajput A.H., Gibson J.M., Lynch T., Dickson D.W., Uitti R.J., Wszolek Z.K., Farrer M.J., Ross O.A. FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov. Disord. 2009, 24:455-459.
33. Xiromerisiou G., Hadjigeorgiou G.M., Eerola J., Fernandez H.H., Tsimourtou V., Mandel R., Hellstrom O., Gwinn-Hardy K., Okun M.S., Tienari P.J., Singleton A.B. BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson's disease in diverse ethnic groups. Neurosci. Lett. 2007, 415:59-63.
34. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
35. Zhou W, Schaack J., Zawada W.M., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 2002, 926:42-50.
36. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.